Cargando…
Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches
BACKGROUND: Immunohistochemistry (IHC) and fluorescent in situ hybridisation (FISH) are currently the most commonly used methods to assess HER2 status. PCR-based assays allow quantitative determination of HER2 amplification (Q-PCR) or overexpression (Q-RT–PCR), but are not routinely used. We evaluat...
Autores principales: | Lehmann-Che, J, Amira-Bouhidel, F, Turpin, E, Antoine, M, Soliman, H, Legres, L, Bocquet, C, Bernoud, R, Flandre, E, Varna, M, de Roquancourt, A, Plassa, L-F, Giacchetti, S, Espié, M, de Bazelaire, C, Cahen-Doidy, L, Bourstyn, E, Janin, A, de Thé, H, Bertheau, P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111154/ https://www.ncbi.nlm.nih.gov/pubmed/21540864 http://dx.doi.org/10.1038/bjc.2011.135 |
Ejemplares similares
-
Changes in allelic imbalances in locally advanced breast cancers after chemotherapy
por: Varna, M, et al.
Publicado: (2007) -
Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15
por: Lehmann-Che, Jacqueline, et al.
Publicado: (2013) -
Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen
por: Bertheau, Philippe, et al.
Publicado: (2007) -
Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer
por: Bousquet, Guilhem, et al.
Publicado: (2017) -
TP53 Status and Response to Treatment in Breast Cancers
por: Varna, Mariana, et al.
Publicado: (2011)